PRESSRELEASE



Shionogi to Announce Personnel Reassignment

OSAKA, Japan, February 27, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) announced that Shionogi will implement the following personnel reassignment as of March 1, 2023.

1. Personnel Reassignments (Effective; March 1, 2023)

1. 1 ersonner keassignments (Errective, March 1, 2025)								
New (or continuing) Position	Name	Present Position						
Healthcare Business Supervisory Unit Integrated Disease Care Division								
Vice President, Corporate Social Responsibility Department and Senior Director, Office for Stewardship to Proper Use of Medicine and President, Shionogi Smile Heart Co., Ltd.	Hiroyuki Tanaka	Vice President, Corporate Social Responsibility Department and President, Shionogi Smile Heart Co., Ltd.						

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html

				Corporate Executive Meeting	1	
		I			_	
The Annual General Meeting of Shareholders —		Board of Directors		<u></u>	→	
		Chief Executive Officer and Representative Director		Compliance Committee		
	Board of Auditor					
	board of Additor	3				
1		I		i 	_	
R&D Supervisory Unit		Research Division		Laboratory for Drug Discovery and Disease Research		
				Laboratory for Medicinal Chemistry Research		
				Laboratory for Drug Discovery and Development API R&D Laboratory	_	
				Formulation R&D Laboratory		
				Intellectual Property Department		
				intellectual Froperty Department	_	
,		Drug Development and Regulatory Science Division		Project Management Department		
				Clinical Research Department		
				Medical Science Department		
				Regulatory Affairs Department		
				Pharmacovigilance Department		
						Biostatistics Center
		Displayman souties Descayed Division		Laboratory for Bio-Drug Discovery	7	
		Biopharmaceutical Research Division			-	
				Laboratory for Bio-Modality Research	-	
				Analysis and Evaluation Laboratory	_	
				Business Development Department	1	
				Investment Strategy Department	╡	
				investment strategy bepartment	4	
Healthcare Business Supervisory Unit		Pharmaceutical Commercial Division	-	Promotion Department - Region 1	7	
Treditricare Business Supervisory Offic		Thurmaceatear commercial physion		Promotion Department - Region 2		
				Promotion Department - Region 3		
				Promotion Department - Region 4		
				Promotion Department - Region 5		
				Distribution Management Department		
						Sales Promotion Office
						Specialty Product Office
					_	, , , , , , , , , , , , , , , , , , , ,
		Integrated Disease Care Division		New Product Planning Department		
				Medical Affairs Department		Drug Information Center
				Corporate Social Responsibility Department		Office for Children's Bright Future
						Office for Stewardship to Proper Use of Medicine
				New Business Promotion Department		A
						Academia Collaboration Office
				Government Affairs Department	7	
				Vaccine and Diagnostic Drug Department		Diagnostic Drug Office
				vaccine and biagnostic brag beparanent		Partnership Promotion Office
				Tokyo Branch Office		rathership fromodon onice
					_	
Supply Supervisory Unit		Global Business Division		Global Business Department		
				Global Supply Chain Strategy Department		
					_	
Corporate Supervisory Unit		Corporate Strategy Division		Corporate Planning Department		r
				Finance & Accounting Department		Business Administration Office
				Corporate Communications Department		
				Corporate Secretariat		
		Administration Division		Human Resources Department		Human Capital Strategy Office
		Administration division		Tiuman Resources Department		Career Development Office
				Value Chain Support Department		R&D Support Office
				value chain support separament		Healthcare Business Support Office
				General Administration Department	1	
				Legal Affairs Department	1	
				Sustainability Management Department	1	
					_	
	 	DX Promotion Division		IT & Digital Solution Department		
			_	Data Science Department		
					_	
		Corporate Quality Assurance and Ethics & Compliance Management Division		Quality Assurance Department	_	
		(General Marketing Compliance Officer)				Promotional Compliance Office
				F	_	
				Internal Control Department		